Q-omics provides the consensus-scored TMPRSS11CP profile across patient tissues and cancer cell-line models. TMPRSS11CP expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TMPRSS11CP is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TMPRSS11CP RNA expression shows 15,824 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where TMPRSS11CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMPRSS11CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMPRSS11CP survival associations across molecular data types. TMPRSS11CP RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMPRSS11CP RNA expression–survival associations across cancer types. High TMPRSS11CP expression shows unfavorable associations in UCEC, KIRC, UVM and CHOL, but favorable associations in BLCA and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TMPRSS11CP RNA expression.
This table summarizes TMPRSS11CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMPRSS11CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMPRSS11CP shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRC, STAD, CHOL and PRAD. The KIRC box plot shows higher TMPRSS11CP RNA expression in tumor versus normal tissue (log2 FC = +0.101, t-test p = .009).
This table shows molecular features associated with TMPRSS11CP in patient tissues and cancer cell lines. In patient samples, TMPRSS11CP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
